# Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

> **NCT02651870** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 135 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Candesartan 16mg
- **DRUG:** Amlodipine 5mg
- **DRUG:** Amlodipine 10mg

## Key facts

- **NCT ID:** NCT02651870
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-22
- **Primary completion:** 2016-02-25
- **Final completion:** 2016-02-29
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02651870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02651870, "Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02651870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*